The dynamics of the head and neck squamous cell carcinoma
market are anticipated to change in the coming years owing to the
improvement in the diagnosis methodologies, incremental healthcare
spending across the world, and the expected launch of emerging
therapies
LAS
VEGAS, Sept. 18, 2023 /PRNewswire/ --
DelveInsight's Head and Neck Squamous Cell Carcinoma Market
Insights report includes a comprehensive understanding of
current treatment practices, head and neck squamous cell carcinoma
emerging drugs, market share of individual therapies, and current
and forecasted market size from 2019 to 2032, segmented into 7MM
[the United States, the EU-4
(Italy, Spain, France, and Germany), the United
Kingdom, and Japan].
Key Takeaways from the Head and Neck Squamous Cell Carcinoma
Market Report
- As per DelveInsight analysis, the head and neck squamous cell
carcinoma market is expected to grow positively at a
significant CAGR during the study period (2019–2032).
- Head and neck cancers account for approximately 4% of
all cancers in the United States.
These cancers are more than twice as common among men as they are
among women. Head and neck cancers are also diagnosed more often
among people over age 50 than they are among younger
people.
- Leading head and neck squamous cell carcinoma companies
such as Pfizer, Adlai Nortye Biopharma Co., Ltd., Merck Sharp
& Dohme LLC, Eisai Inc., AstraZeneca, Innate Pharma, Roche,
GlaxoSmithKline, Nanobiotix, Rakuten Medical, Inc., BeiGene, IO
Biotech, Incyte Corporation, NATCO Pharma Ltd., Galecto Biotech AB,
Surface Oncology, Precision Biologics, Inc, Replimune Inc.,
Regeneron Pharmaceuticals, Aveta Biomics, Inc., Calliditas
Therapeutics AB, Vaccinex Inc., BioNTech SE, Vyriad, Inc.,
MitoImmune Therapeutics, Cytovation AS, MedImmune LLC, Kura
Oncology, Inc., Genentech, Inc., Seagen Inc., Telix International
Pty Ltd, Immutep S.A.S., Iovance Biotherapeutics, Inc.,
OncoResponse, Inc., Rakuten Medical, Inc., Hookipa Biotech GmbH,
NKGen Biotech, Inc., invoX Pharma Limited, Merus N.V., Fusion
Pharmaceuticals Inc., and others are developing novel head and
neck squamous cell carcinoma drugs that can be available in the
head and neck squamous cell carcinoma market in the coming
years.
- Some key therapies for head and neck squamous cell
carcinoma treatment include Cetuximab, Buparlisib &
Paclitaxel, Pembrolizumab, Monalizumab + Cetuximab, Atezolizumab,
Feladilimab & Pembrolizumab, NBTXR3, ASP-1929
Photoimmunotherapy, Tislelizumab (BGB-A317), IO102-103,
Ruxolitinib, NRC-2694-A, GB1211, SRF114, NEO-201 in combination
with pembrolizumab, RP3, CMP-001,
APG-157, and others.
Discover which therapies are expected to grab the major head and
neck squamous cell carcinoma market share @ Head and Neck
Squamous Cell Carcinoma Market Report
Head and Neck Squamous Cell Carcinoma Overview
Head and neck squamous cell carcinoma (HNSCC) is a type of
cancer that originates in the squamous cells lining the mucous
membranes of the head and neck region. This encompasses areas such
as the mouth, throat, voice box, and the various structures in the
neck. The primary risk factors for HNSCC include tobacco use,
excessive alcohol consumption, and human papillomavirus (HPV)
infection. HNSCC manifests with a spectrum of symptoms contingent
on its location and stage. Persistent sore throat, difficulty
swallowing, hoarseness, unexplained ear pain, and the appearance of
lumps or sores in the mouth, throat, or neck are common indicators.
Swelling in the neck may also signify the spread of cancer to lymph
nodes. Imaging techniques like X-rays, CT scans, MRI, or PET scans
help ascertain the tumor's extent and its potential spread.
Endoscopy, using a flexible, illuminated tube, allows direct
visualization of the throat and vocal cords. For oropharyngeal
cancers, HPV testing is conducted to establish the cause and guide
treatment strategies.
Head and Neck Squamous Cell Carcinoma Epidemiology
Segmentation
The head and neck squamous cell carcinoma epidemiology
section provides insights into the historical and current head and
neck squamous cell carcinoma patient pool and forecasted
trends for individual seven major countries. It helps to recognize
the causes of current and forecasted trends by exploring numerous
studies and views of key opinion leaders.
The head and neck squamous cell carcinoma market
report proffers epidemiological analysis for the study period
2019–2032 in the 7MM segmented into:
- HNSCC Incident Cases
- HNSCC Site-specific Incident Cases
- HNSCC Stage-specific Incident Cases
- HNSCC Radiation Therapy Eligible Cases
Head and Neck Squamous Cell Carcinoma Treatment
Market
The head and neck squamous cell carcinoma treatment is a
multifaceted endeavor, tailored to the specifics of each case.
Typically, it encompasses a combination of surgical intervention,
radiation therapy, and chemotherapy, often complemented by targeted
therapies or immunotherapy depending on the stage and location of
the cancer. Surgery aims to excise localized tumors and may require
reconstructive procedures for functional and cosmetic restoration.
Radiation therapy employs high-energy X-rays to target cancer
cells, while chemotherapy and targeted therapies aim to slow down
or destroy malignant cells. Immunotherapy harnesses the body's
immune system to combat cancer. Supportive care, clinical trials,
and lifestyle adjustments also play pivotal roles in optimizing
treatment outcomes, emphasizing the importance of a personalized
approach guided by a healthcare team to balance effectiveness and
quality of life.
Cetuximab, a monoclonal antibody targeting the epidermal
growth factor receptor, and pembrolizumab and nivolumab, monoclonal
antibodies targeting programmed cell death 1 (PD-1) are now
approved by the US Food and Drug Administration for the treatment
of recurrent and metastatic HNSCC. The current unmet needs in the
disease domain are the last ten years of minimal innovation for
patients with locally advanced HNSCC. Despite intensive
standard-of-care treatment with high-dose chemotherapy combined
with radiation, a considerable number of patients with locally
advanced HNSCC relapse. Patients' quality of life frequently
deteriorates following therapy, which is frequently related to
treatment toxicities. Patients also have few therapy alternatives
after progressing off PD-1 inhibitors, which represents a
significant unmet HNSCC market need.
To know more about head and neck squamous cell carcinoma
treatment, visit @ Head and Neck Squamous Cell Carcinoma
Treatment Drugs
Key Head and Neck Squamous Cell Carcinoma Therapies and
Companies
- Cetuximab: Pfizer
- Buparlisib & Paclitaxel: Adlai Nortye Biopharma Co.,
Ltd.
- Pembrolizumab: Merck Sharp & Dohme LLC/Eisai Inc.
- Monalizumab + Cetuximab: AstraZeneca/Innate Pharma
- Atezolizumab: Roche
- Feladilimab & Pembrolizumab: GlaxoSmithKline/Merck
- NBTXR3: Nanobiotix
- ASP-1929 Photoimmunotherapy: Rakuten Medical, Inc.
- Tislelizumab (BGB-A317): BeiGene
- IO102-103: IO Biotech
- Ruxolitinib: Incyte Corporation
- NRC-2694-A: NATCO Pharma Ltd.
- GB1211: Galecto Biotech AB
- SRF114: Surface Oncology
- NEO-201 in combination with pembrolizumab: Precision Biologics,
Inc
- RP3: Replimune Inc.
- CMP-001: Regeneron Pharmaceuticals
- APG-157: Aveta Biomics, Inc.
Learn more about the FDA-approved drugs for head and neck
squamous cell carcinoma @ Drugs for Head and Neck Squamous
Cell Carcinoma Treatment
Head and Neck Squamous Cell Carcinoma Market Dynamics
The HNSCC market dynamics have been undergoing significant
shifts in recent years. Several factors are driving these changes.
Firstly, there has been a growing understanding of the
molecular and genetic basis of HNSCC, leading to the
development of targeted therapies and personalized treatment
approaches. This has brought about a paradigm shift in treatment
strategies, moving away from the traditional one-size-fits-all
approach to more tailored and effective therapies.
Secondly, the increasing prevalence of risk factors such
as smoking, alcohol consumption, and human papillomavirus (HPV)
infection has contributed to the rising incidence of HNSCC. This,
in turn, is expanding the patient pool and driving demand
for novel treatment options. Furthermore, the healthcare landscape
is evolving, with a focus on value-based care and cost-effective
treatment solutions. HNSCC market dynamics are influenced by
the need for therapies that not only improve patient outcomes but
also offer economic benefits to healthcare systems and payers.
The HNSCC market faces several significant barriers that impact
its growth and development. Firstly, the complexity of the
disease itself poses a formidable challenge. HNSCC encompasses
a heterogeneous group of cancers, each with its own unique
characteristics and treatment requirements. This diversity
complicates drug development, as therapies must be tailored
to specific subsets of patients.
Secondly, clinical trials for HNSCC therapies can be lengthy
and costly. The need for extensive patient recruitment, complex
trial designs, and long-term follow-ups adds to the financial
burden on pharmaceutical companies. Additionally, the
competitive landscape for oncology treatments is intense, making it
difficult for emerging therapies to gain HNSCC market access
and market share.
Report
Metrics
|
Details
|
Study Period
|
2019–2032
|
Coverage
|
7MM [The United States,
the EU-4 (Germany, France, Italy, and Spain), the United Kingdom,
and Japan]
|
Key Head and Neck
Squamous Cell Carcinoma Companies
|
Pfizer, Adlai Nortye
Biopharma Co., Ltd., Merck Sharp & Dohme LLC, Eisai Inc.,
AstraZeneca, Innate Pharma, Roche, GlaxoSmithKline, Nanobiotix,
Rakuten Medical, Inc., BeiGene, IO Biotech, Incyte Corporation,
NATCO Pharma Ltd., Galecto Biotech AB, Surface Oncology, Precision
Biologics, Inc, Replimune Inc., Regeneron Pharmaceuticals, Aveta
Biomics, Inc., Calliditas Therapeutics AB, Vaccinex Inc., BioNTech
SE, Vyriad, Inc., MitoImmune Therapeutics, Cytovation AS, MedImmune
LLC, Kura Oncology, Inc., Genentech, Inc., Seagen Inc., Telix
International Pty Ltd, Immutep S.A.S., Iovance Biotherapeutics,
Inc., OncoResponse, Inc., Rakuten Medical, Inc., Hookipa Biotech
GmbH, NKGen Biotech, Inc., invoX Pharma Limited, Merus N.V., Fusion
Pharmaceuticals Inc., and
others
|
Key Head and Neck Squamous Cell Carcinoma
Therapies
|
Cetuximab, Buparlisib
& Paclitaxel, Pembrolizumab, Monalizumab + Cetuximab,
Atezolizumab, Feladilimab & Pembrolizumab, NBTXR3, ASP-1929
Photoimmunotherapy, Tislelizumab (BGB-A317), IO102-103,
Ruxolitinib, NRC-2694-A, GB1211, SRF114, NEO-201 in combination
with pembrolizumab, RP3, CMP-001, APG-157, and others
|
Scope of the Head and Neck Squamous Cell
Carcinoma Market Report
- Therapeutic Assessment: Head and Neck Squamous Cell
Carcinoma current marketed and emerging therapies
- Head and Neck Squamous Cell Carcinoma Market
Dynamics: Conjoint Analysis of Emerging Head and Neck
Squamous Cell Carcinoma Drugs
- Competitive Intelligence Analysis: SWOT analysis
and Market entry strategies
- Unmet Needs, KOL's views, Analyst's views, Head and Neck
Squamous Cell Carcinoma Market Access and Reimbursement
Discover more about head and neck squamous cell carcinoma drugs
in development @ Head and Neck Squamous Cell Carcinoma Clinical
Trials
Table of Contents
1.
|
Head and Neck Squamous
Cell Carcinoma Market Key
Insights
|
2.
|
Head and Neck Squamous
Cell Carcinoma Market Report
Introduction
|
3.
|
Head and Neck Squamous
Cell Carcinoma Market Overview at a Glance
|
4.
|
Head and Neck Squamous
Cell Carcinoma Market Executive
Summary
|
5.
|
Disease Background and
Overview
|
6.
|
Head and Neck Squamous
Cell Carcinoma Treatment and
Management
|
7.
|
Head and Neck Squamous
Cell Carcinoma Epidemiology and
Patient Population
|
8.
|
Patient
Journey
|
9.
|
Head and Neck Squamous
Cell Carcinoma Marketed Drugs
|
10.
|
Head and Neck Squamous
Cell Carcinoma Emerging
Drugs
|
11.
|
Seven Major
Head and Neck Squamous Cell
Carcinoma Market
Analysis
|
12.
|
Head and Neck Squamous
Cell Carcinoma Market
Outlook
|
13.
|
Potential of Current
and Emerging Therapies
|
14.
|
KOL Views
|
15.
|
Unmet Needs
|
16.
|
SWOT
Analysis
|
17.
|
Appendix
|
18.
|
DelveInsight
Capabilities
|
19.
|
Disclaimer
|
20.
|
About
DelveInsight
|
Related Reports
Recurrent Head and Neck Squamous Cell
Carcinoma Pipeline
Recurrent Head and Neck Squamous Cell Carcinoma Pipeline
Insight – 2023 report provides comprehensive insights
about the pipeline landscape, pipeline drug profiles, including
clinical and non-clinical stage products, and the
key recurrent head and neck squamous cell
carcinoma companies, including CEL-SCI, Junshi Biosciences,
Coherus, Exelixis, Immutep S.A.S., Merck Sharp & Dohme LLC,
Iovance Biotherapeutics, BeiGene, Akeso, Chia Tai-Tianqing, Kura Oncology, Hoffmann-La
Roche, Eli Lilly and Company, among others.
Head and Neck Squamous Cell Carcinoma Epidemiology
Head and Neck Squamous Cell Carcinoma Epidemiology
Forecast – 2032 report delivers an in-depth understanding
of the disease, historical and forecasted head and neck squamous
cell carcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy,
France, and the United Kingdom), and Japan.
Recurrent Head and Neck Squamous Cell
Carcinoma Market
Recurrent Head and Neck Squamous Cell Carcinoma Market
Insight, Epidemiology, and Market Forecast – 2032 report
delivers an in-depth understanding of the market trends, market
drivers, market barriers, and key recurrent head and neck squamous
cell carcinoma companies, including CEL-SCI, Junshi Biosciences,
Coherus, Exelixis, Immutep S.A.S., Merck Sharp & Dohme LLC,
Iovance Biotherapeutics, BeiGene, Akeso, Chia Tai-Tianqing, Kura Oncology, Hoffmann-La
Roche, Eli Lilly and Company, among others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market
Research firm focused exclusively on life sciences. It supports
pharma companies by providing comprehensive end-to-end solutions to
improve their performance. Get hassle-free access to all the
healthcare and pharma market research reports through our
subscription-based platform PharmDelve.
Contact Us
Shruti
Thakur
info@delveinsight.com
+1(919)321-6187
www.delveinsight.com
Logo:
https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/head-and-neck-squamous-cell-carcinoma-market-to-witness-upsurge-in-growth-by-2032-assesses-delveinsight--key-companies-in-the-market---pfizer-merck-eisai-astrazeneca-innate-roche-glaxosmithkline-beigene-io-biotech-incyt-301930322.html
SOURCE DelveInsight Business Research, LLP